News
SLP
49.41
-1.26%
-0.63
Weekly Report: what happened at SLP last week (0513-0517)?
Weekly Report · 1d ago
Simulations Plus (SLP) Launches GPX to Advance PBPK Modeling
NASDAQ · 5d ago
Craig-Hallum Reaffirms Their Buy Rating on Simulations Plus (SLP)
TipRanks · 5d ago
Simulations Plus: Reliance On Consulting And Acquisitions Creates Doubts
Seeking Alpha · 05/14 05:16
Weekly Report: what happened at SLP last week (0506-0510)?
Weekly Report · 05/13 09:20
Simulations Plus, Inc.'s (NASDAQ:SLP) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Simulations Plus' (NASDAQ:SLP) stock increased by 26% over the past three months. The ROE of Simulations Plus is 5.9% and is similar to the average for its industry. The company's net income growth is also higher than the industry average. Return on equity is a measure of how efficiently a company can generate profits. Simulations plus has a 5.8% ROE.
Simply Wall St · 05/07 10:03
Weekly Report: what happened at SLP last week (0429-0503)?
Weekly Report · 05/06 09:22
Weekly Report: what happened at SLP last week (0422-0426)?
Weekly Report · 04/29 09:23
Ex-Dividend Reminder: Blackstone, Simulations Plus and Celanese Corp
NASDAQ · 04/24 14:43
Weekly Report: what happened at SLP last week (0415-0419)?
Weekly Report · 04/22 09:21
Simulations Plus (NASDAQ:SLP): Promising Potential in Biotech Software
TipRanks · 04/16 09:48
Weekly Report: what happened at SLP last week (0408-0412)?
Weekly Report · 04/15 09:20
YieldBoost Simulations Plus From 0.5% To 16.1% Using Options
NASDAQ · 04/09 15:35
Simulations Plus (SLP) DILIsym Software Licenses Renewed by FDA
NASDAQ · 04/08 13:06
Weekly Report: what happened at SLP last week (0401-0405)?
Weekly Report · 04/08 09:21
Why Reliance Global Group Shares Are Trading Lower By Around 11%; Here Are 20 Stocks Moving Premarket
Reliance Global Group, Inc. Shares fell sharply in today’s pre-market trading after reporting financial results for the year ended Dec 31, 2023. The company posted a net loss of $12.0 million for 2023, compared to net income of $6.5 million in 2022. Gainers MediaCo Holding Inc. Rose 175% to $3.85 in pre- market trading.
Benzinga · 04/05 09:45
Health Care Sector Update for 04/04/2024: FNA, SLP, ADCT, ALUR
NASDAQ · 04/04 20:03
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
STAAR Surgical shares jumped 13.3% to $44.30 on Thursday. The company issued strong preliminary first-quarter net sales guidance. TC Biopharm (Holdings) Plc shares climbed 130.1% in the mid-day session.
Benzinga · 04/04 17:21
Simulations Plus stock jumps 25% amid FDA renewal, earnings report
Simulations Plus stock jumps 25% amid FDA renewal, earnings report. The company announced the FDA had renewed its license to the DILIsym toxicology software platform for the seventh year. Simulations Plus reported fiscal Q2 revenue rose 18% year-over-year to $18.3M.
Seeking Alpha · 04/04 16:19
Simulations Plus Shares Rise 27% Following FDA's License Renewal for Dilisym Software Platform
Shares of Simulations Plus are up 27% at $48.72. The company says the licenses to its Dilisym software platform have been renewed by the FDA. The stock is up about 6% for the year to date. The software predicts the potential for drug-induced liver injury.
Dow Jones · 04/04 15:52
More
Webull provides a variety of real-time SLP stock news. You can receive the latest news about Simulations Plus Inc through multiple platforms. This information may help you make smarter investment decisions.
About SLP
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. The Company's segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. Its software and consulting services are provided to various industries, including biotechnology and cosmetics.